Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
Open Access
- 23 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Virology Journal
- Vol. 18 (1), 1-17
- https://doi.org/10.1186/s12985-021-01624-x
Abstract
The COVID-19 pandemic has put healthcare infrastructures and our social and economic lives under unprecedented strain. Effective solutions are needed to end the pandemic while significantly lessening its further impact on mortality and social and economic life. Effective and widely-available vaccines have appropriately long been seen as the best way to end the pandemic. Indeed, the current availability of several effective vaccines are already making a significant progress towards achieving that goal. Nevertheless, concerns have risen due to new SARS-CoV-2 variants that harbor mutations against which current vaccines are less effective. Furthermore, some individuals are unwilling or unable to take the vaccine. As health officials across the globe scramble to vaccinate their populations to reach herd immunity, the challenges noted above indicate that COVID-19 therapeutics are still needed to work alongside the vaccines. Here we describe the impact that neutralizing antibodies have had on those with early or mild COVID-19, and what their approval for early management of COVID-19 means for other viral entry inhibitors that have a similar mechanism of action. Importantly, we also highlight studies that show that therapeutic strategies involving various viral entry inhibitors such as multivalent antibodies, recombinant ACE2 and miniproteins can be effective not only for pre-exposure prophylaxis, but also in protecting against SARS-CoV-2 antigenic drift and future zoonotic sarbecoviruses.Keywords
This publication has 165 references indexed in Scilit:
- Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 DomainsInternational Journal of Molecular Sciences, 2018
- Identification of a Novel Inhibitor against Middle East Respiratory Syndrome CoronavirusViruses, 2017
- Structure, Function, and Evolution of Coronavirus Spike ProteinsAnnual Review of Virology, 2016
- Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotypeCellular Immunology, 2012
- Aprotinin and similar protease inhibitors as drugs against influenzaAntiviral Research, 2011
- Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitorVirology, 2006
- Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interactionAntiviral Research, 2006
- Screening and Identification of Linear B-Cell Epitopes and Entry-Blocking Peptide of Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus Using Synthetic Overlapping Peptide LibraryJournal of Combinatorial Chemistry, 2005
- Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated CoronavirusAntiviral Therapy, 2005
- Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptidesProceedings of the National Academy of Sciences of the United States of America, 2004